查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570791

同种异体干细胞市场：按类型、细胞来源、应用和最终用户划分 - 2025-2030 年全球预测

Allogeneic Stem Cells Market by Type (Cord Blood Transplant, Donor Lymphocyte Infusion, T-cell depleted Transplant), Cell Source (Adipose Tissue, Bone Marrow, Peripheral Blood Stem Cell), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年异体干细胞市值为2.7834亿美元，预计到2024年将达到3.2834亿美元，复合年增长率为18.83%，到2030年将达到9.3134亿美元。

同种异体干细胞使用的细胞来自捐赠者，与取自患者体内的自体细胞不同。它在再生医学中极为重要，可以治疗血液疾病、免疫疾病、组织再生等。对同种异体干细胞的需求源于其多功能，它为移植提供了可再生的细胞供应，并具有治疗传统治疗方法难以治癒的疾病的潜力。其应用涵盖肿瘤学、心血管学和神经学，主要最终用户为医院、研究机构和生物製药公司。市场成长受到慢性病日益流行、细胞治疗方法的进步以及鼓励创新的法律规范的影响。新的商机包括快速发展的生物技术、增强的冷冻保存技术以及老龄化黄斑部病变等新治疗领域的开拓。然而，免疫排斥、伦理问题、严格的法规和高成本等挑战可能会阻碍进展。改善移植物抗宿主疾病的结果和开发多功能供体细胞的研究对于克服这些限制至关重要。该市场的特点是技术快速进步，重点是个人化医疗以及科学和商业领域的合作研究。创新领域包括使用基因编辑技术来提高干细胞的功效、组织工程3D生物列印的进步以及整合人工智慧来优化细胞处理。由于该细分市场充满活力，因此鼓励公司投资于坚实的研发、建立策略伙伴关係并优先考虑监管协调。也应该专注于扩大临床试验网络和病患教育。积极主动地解决道德问题和开发大规模生产基础设施将有助于市场进入。最终，创造一个促进创新和跨学科对话的环境将是同种异体干细胞市场成功的关键。

主要市场统计
基准年[2023] 27834万美元
预测年份 [2024] 3.2834亿美元
预测年份 [2030] 93134万美元
复合年增长率（%） 18.83%

市场动态：揭示快速发展的同种异体干细胞市场的关键市场洞察

供需的动态交互作用正在改变同种异体干细胞市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，以及消费行为如何影响製造成本，还可以更清楚地了解其对采购趋势的影响。

波特五力：驾驭同种异体干细胞市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解异体干细胞市场的外部影响

外部宏观环境因素在塑造同种异体干细胞市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解异体干细胞市场的竞争状况

同种异体干细胞市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV定位矩阵同种异体干细胞市场供应商绩效评估

FPNV定位矩阵是评估异体干细胞市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议描绘同种异体干细胞市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，同种异体干细胞市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告提供了涵盖主要焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细审查，包括行业主要企业的广泛资料、市场覆盖范围和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有产业的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检视市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病和退化性疾病盛行率增加
      • 消费者对个人化医疗的偏好日益增长
      • 扩大干细胞研究和开发活动
    • 抑制因素
      • 开发同种异体干细胞疗法相关的高成本
    • 机会
      • 扩大联合开发计划的策略合作与伙伴关係
      • 有利的政府措施和增加的私人资金
    • 任务
      • 严格的法规遵从性和製造流程的复杂性
  • 市场区隔分析
    • 类型：将脐带血移植系统扩展到儿科患者
    • 最终用户：生物技术和製药公司在干细胞疗法开发中越来越多地使用同种异体干细胞
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章同种异体干细胞市场：依类型

  • 介绍
  • 脐带血移植
  • 供体淋巴细胞输注
  • T细胞消融移植
  • 未经修饰的干细胞移植

第七章同种异体干细胞市场：依细胞来源分类

  • 介绍
  • 脂肪组织
  • 骨髓
  • 週边血干细胞
  • 脐带血

第八章同种异体干细胞市场：依应用分类

  • 介绍
  • 自体免疫疾病
  • 心血管疾病
  • 肌肉骨骼疾病
  • 肿瘤学

第九章同种异体干细胞市场：依最终用户分类

  • 介绍
  • 学术研究所
  • 生物技术和製药公司
  • 医院/诊所
  • 干细胞库

第十章美洲同种异体干细胞市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太同种异体干细胞市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲同种异体干细胞市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • VetStem Inc. 推出 PrecisePRP Canine，这是一种具有先进优势的创新兽医 PRP 治疗方法
    • Cartherics 和 TiCARos 合作，透过结合创新的 CLIP-CAR 和 NK 细胞平台来推进癌症治疗研究和商业化
    • Selecta Biosciences 和 Cartesian Therapeutics 联手，凭藉强大的产品线和大量资金，推进针对自体免疫疾病的 RNA 细胞疗法
  • 战略分析和建议
Product Code: MRR-4969A8FF998A

The Allogeneic Stem Cells Market was valued at USD 278.34 million in 2023, expected to reach USD 328.34 million in 2024, and is projected to grow at a CAGR of 18.83%, to USD 931.34 million by 2030.

Allogeneic stem cells involve the use of donor-derived cells, distinct from autologous cells, sourced from the patient's body. They are pivotal in regenerative medicine, enabling treatments for hematological diseases, immune disorders, and tissue regeneration. The necessity of allogeneic stem cells arises from their potential to treat conditions unmanageable by conventional therapies, providing a renewable supply of cells for transplantation due to their pluripotent nature. Their applications span oncology, cardiovascular, and neurology, with hospitals, research institutes, and biopharmaceutical companies being key end-users. The market growth is influenced by the increasing prevalence of chronic diseases, advancements in cell-based therapies, and supportive regulatory frameworks that encourage innovation. Emerging opportunities include burgeoning biotechnologies, enhanced cryopreservation techniques, and the exploration of new therapeutic areas like age-related macular degeneration. However, challenges such as immunorejection, ethical concerns, stringent regulations, and high costs can impede progress. Research into improving graft-versus-host disease outcomes and developing universal donor cells is essential for overcoming these limitations. The market is characterized by rapid technological advancements, with a focus on personalized medicine and collaborations across scientific and commercial sectors. Innovative areas include the use of gene-editing techniques to enhance stem cell efficacy, advancements in 3D bioprinting for tissue engineering, and the integration of artificial intelligence to optimize cell processing. As the sector is highly dynamic, businesses are recommended to invest in robust R&D, forge strategic partnerships, and prioritize regulatory alignment. The emphasis should also be on expanding clinical trial networks and patient education. A proactive approach in addressing ethical concerns and improving the infrastructure for large-scale production will catalyze market engagement. Ultimately, fostering an environment conducive to innovation and cross-disciplinary dialogue will be key to navigating the allogeneic stem cell market successfully.

KEY MARKET STATISTICS
Base Year [2023] USD 278.34 million
Estimated Year [2024] USD 328.34 million
Forecast Year [2030] USD 931.34 million
CAGR (%) 18.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Allogeneic Stem Cells Market

The Allogeneic Stem Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic and degenerative diseases
    • Rising consumer preference for personalized medicine
    • Growing research and development activity in stem cells
  • Market Restraints
    • High costs associated with development of allogeneic stem cell therapies
  • Market Opportunities
    • Increasing strategic collaborations and partnerships for co-development projects
    • Favorable government initiatives and increasing private fundings
  • Market Challenges
    • Stringent regulatory compliance and complexities in manufacturing processes

Porter's Five Forces: A Strategic Tool for Navigating the Allogeneic Stem Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Allogeneic Stem Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Allogeneic Stem Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Allogeneic Stem Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Allogeneic Stem Cells Market

A detailed market share analysis in the Allogeneic Stem Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Allogeneic Stem Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Allogeneic Stem Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Allogeneic Stem Cells Market

A strategic analysis of the Allogeneic Stem Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Stem Cells Market, highlighting leading vendors and their innovative profiles. These include AgeX Therapeutics, Athersys, Inc., BioCardia, Inc., Bluebird Bio, Inc., BrainStorm Cell Therapeutics, Inc., Capricor Therapeutics, Inc, Cellectis SA, Celularity Inc., Fate Therapeutics, Inc., Gamida Cell Ltd., Helocyte, Inc., Hope Biosciences, LLC, ImmunityBio, Inc., JCR Pharmaceuticals Co., Ltd., Kadimastem Ltd., Lineage Cell Therapeutics, Inc., Lisata Therapeutics Inc., Mesoblast Limited, Pharmicell Co., Ltd., Pluristem Therapeutics Inc., ReNeuron Group plc, RoosterBio, Inc., SanBio, Inc., Sanofi S.A, Smith & Nephew plc, Stemedica Cell Technologies, Inc., Stempeutics Research Pvt Ltd, Vertex Pharmaceuticals Incorporated, and Vita Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Allogeneic Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cord Blood Transplant, Donor Lymphocyte Infusion, T-cell depleted Transplant, and Unmodified Stem Cell Transplant.
  • Based on Cell Source, market is studied across Adipose Tissue, Bone Marrow, Peripheral Blood Stem Cell, and Umbilical Cord Blood.
  • Based on Application, market is studied across Autoimmune Disease, Cardiovascular Disease, Musculoskeletal Disease, and Oncology.
  • Based on End-User, market is studied across Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, and Stem Cell Banks.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic and degenerative diseases
      • 5.1.1.2. Rising consumer preference for personalized medicine
      • 5.1.1.3. Growing research and development activity in stem cells
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with development of allogeneic stem cell therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing strategic collaborations and partnerships for co-development projects
      • 5.1.3.2. Favorable government initiatives and increasing private fundings
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory compliance and complexities in manufacturing processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of cord blood transplant system for pediatric patients
    • 5.2.2. End-users: Rising usage of allogeneic stem cells in biotechnology and pharmaceutical companies for development of stem cell therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Allogeneic Stem Cells Market, by Type

  • 6.1. Introduction
  • 6.2. Cord Blood Transplant
  • 6.3. Donor Lymphocyte Infusion
  • 6.4. T-cell depleted Transplant
  • 6.5. Unmodified Stem Cell Transplant

7. Allogeneic Stem Cells Market, by Cell Source

  • 7.1. Introduction
  • 7.2. Adipose Tissue
  • 7.3. Bone Marrow
  • 7.4. Peripheral Blood Stem Cell
  • 7.5. Umbilical Cord Blood

8. Allogeneic Stem Cells Market, by Application

  • 8.1. Introduction
  • 8.2. Autoimmune Disease
  • 8.3. Cardiovascular Disease
  • 8.4. Musculoskeletal Disease
  • 8.5. Oncology

9. Allogeneic Stem Cells Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Biotechnology & Pharmaceutical Companies
  • 9.4. Hospitals & Clinics
  • 9.5. Stem Cell Banks

10. Americas Allogeneic Stem Cells Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Allogeneic Stem Cells Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Allogeneic Stem Cells Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. VetStem Inc. launches PrecisePRP Canine, revolutionary veterinary PRP treatment with advance benefits
    • 13.3.2. Cartherics and TiCARos join forces combining innovative CLIP-CAR and NK cell platforms to advance cancer treatment research and commercialization
    • 13.3.3. Selecta Biosciences and Cartesian Therapeutics merge to advance RNA cell therapy for autoimmune diseases with a strong pipeline and substantial financial backing
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AgeX Therapeutics
  • 2. Athersys, Inc.
  • 3. BioCardia, Inc.
  • 4. Bluebird Bio, Inc.
  • 5. BrainStorm Cell Therapeutics, Inc.
  • 6. Capricor Therapeutics, Inc
  • 7. Cellectis SA
  • 8. Celularity Inc.
  • 9. Fate Therapeutics, Inc.
  • 10. Gamida Cell Ltd.
  • 11. Helocyte, Inc.
  • 12. Hope Biosciences, LLC
  • 13. ImmunityBio, Inc.
  • 14. JCR Pharmaceuticals Co., Ltd.
  • 15. Kadimastem Ltd.
  • 16. Lineage Cell Therapeutics, Inc.
  • 17. Lisata Therapeutics Inc.
  • 18. Mesoblast Limited
  • 19. Pharmicell Co., Ltd.
  • 20. Pluristem Therapeutics Inc.
  • 21. ReNeuron Group plc
  • 22. RoosterBio, Inc.
  • 23. SanBio, Inc.
  • 24. Sanofi S.A
  • 25. Smith & Nephew plc
  • 26. Stemedica Cell Technologies, Inc.
  • 27. Stempeutics Research Pvt Ltd
  • 28. Vertex Pharmaceuticals Incorporated
  • 29. Vita Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. ALLOGENEIC STEM CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. ALLOGENEIC STEM CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ALLOGENEIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ALLOGENEIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALLOGENEIC STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALLOGENEIC STEM CELLS MARKET DYNAMICS
  • TABLE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CORD BLOOD TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DONOR LYMPHOCYTE INFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY T-CELL DEPLETED TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UNMODIFIED STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MUSCULOSKELETAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY STEM CELL BANKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. ALLOGENEIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. ALLOGENEIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023